American Century Companies’s BridgeBio Pharma BBIO Stock Holding History

American Century Companies’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$46.3M	Sell	621,494 -468,832	-43%	-$32.8M	0.02%	888
2026 Q1	$81M	Sell	1,090,326 -16,494	-1%	-$1.2M	0.04%	526
2025 Q4	$84.7M	Buy	1,106,820 +30,234	+3%	+$1.98M	0.04%	490
2025 Q3	$55.9M	Sell	1,076,586 -13,548	-1%	-$661K	0.03%	655
2025 Q2	$47.1M	Buy	1,090,134 +62,646	+6%	+$2.28M	0.03%	702
2025 Q1	$35.5M	Buy	1,027,488 +11,760	+1%	+$397K	0.02%	769
2024 Q4	$27.9M	Buy	1,015,728 +88,882	+10%	+$2.3M	0.02%	897
2024 Q3	$23.6M	Sell	926,846 -169,888	-15%	-$4.46M	0.01%	953
2024 Q2	$27.8M	Buy	1,096,734 +182,623	+20%	+$4.99M	0.02%	810
2024 Q1	$28.3M	Buy	914,111 +442,245	+94%	+$15M	0.02%	790
2023 Q4	$19M	Buy	471,866 +163,574	+53%	+$4.91M	0.01%	894
2023 Q3	$8.13M	Buy	308,292 +297,167	+2,671%	+$8.43M	0.01%	1144
2023 Q2	$191K	Buy	11,125 +280	+3%	+$4.21K	﹤0.01%	2537
2023 Q1	$186K	Sell	10,845 -125	-1%	-$1.46K	﹤0.01%	2440
2022 Q4	$83.6K	Sell	10,970 -325,456	-97%	-$3.12M	﹤0.01%	2482
2022 Q3	$3.34M	Buy	336,426 +3,058	+0.9%	+$31.8K	﹤0.01%	1260
2022 Q2	$3.03M	Sell	333,368 -3,164	-0.9%	-$26.5K	﹤0.01%	1290
2022 Q1	$3.42M	Buy	336,532 +130,465	+63%	+$1.34M	﹤0.01%	1229
2021 Q4	$3.44M	Sell	206,067 -53,349	-21%	-$2.26M	﹤0.01%	1162
2021 Q3	$12.2M	Sell	259,416 -408	-0.2%	-$21.9K	0.01%	790
2021 Q2	$15.8M	Buy	259,824 +11,026	+4%	+$630K	0.01%	716
2021 Q1	$15.3M	Sell	248,798 -4,067	-2%	-$266K	0.01%	695
2020 Q4	$18M	Buy	252,865 +29,898	+13%	+$1.44M	0.01%	642
2020 Q3	$8.37M	Buy	222,967 +26,726	+14%	+$841K	0.01%	743
2020 Q2	$6.4M	Buy	+196,241	New	+$5.98M	0.01%	747

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

American Century Companies's BBIO Position: Q2 2026 in Review

American Century Companies reduced its BridgeBio Pharma (BBIO) stake by 43% in Q2 2026, selling an estimated $32.8M and leaving 621,494 shares worth $46.3M. The position accounts for 0.02% of the portfolio, ranked #888.

American Century Companies first reported a position in BBIO in Q2 2020 and has held it in 25 quarters since. The position peaked at $84.7M in Q4 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

American Century Companies held 621,494 shares of BridgeBio Pharma worth $46.3M as of Q2 2026.
American Century Companies sold 468,832 BridgeBio Pharma shares in Q2 2026, an estimated $32.8M.
BridgeBio Pharma made up 0.02% of American Century Companies's portfolio in Q2 2026, its #888 holding.
American Century Companies first reported a position in BridgeBio Pharma in Q2 2020 and has held it in 25 quarters since.
American Century Companies's BridgeBio Pharma position peaked at $84.7M in Q4 2025.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on American Century Companies's 13F filing for Q2 2026, filed 12 Aug 2026.